Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide
Source: SeekingAlpha
2026-01-30 01:41:43 ET
Thesis
Read the full article on Seeking Alpha
For further details see:
Protagonist Therapeutics: Assessing The 2026 Upside For Icotrokinra And Rusfertide
Protagonist Therapeutics Inc.
NASDAQ: PTGX
PTGX Trading
1.66% G/L:
$96.65 Last:
202,192 Volume:
$96.02 Open:
PTGX Latest News
March 02, 2026 02:00:00 am
Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera
February 25, 2026 05:15:00 pm
CORRECTION: Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026 04:05:00 pm
Protagonist Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 25, 2026 03:48:39 pm
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
PTGX Stock Data
$5,268,820,330
53,263,347
0.64%
112
N/A
Biotechnology & Life Sciences
Healthcare
US
Newark
